Lowest Price Guaranteed From USD 5,899
Published
April 2023
Pages
210
View Count
1769
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
Driven by numerous developmental breakthroughs and encouraging clinical trial results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, this therapeutic modality has garnered considerable attention from the players engaged in the pharmaceutical industry. In fact, in the past few years, close to 30 cell and gene therapies have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. The recent approval of more than five CAR-T cell therapies have further fueled the interest in development of such cellular therapies. However, despite various advantages, adverse events associated with genetically modified gene and cell therapies, including neurotoxicity, cytokine release syndrome (CRS), on-target / off-tumor toxicity and graft-versus-host disease (GVHD), are some of the known limitations of such therapeutic modalities. As a result, the industry is actively seeking various tools / methods to mitigate this challenge. Among the various approaches to enhance the safety profiles of ACTs, safety switch / gene switch / kill switch systems (which are the regulatory sites on genes capable of switching on / off transcription and translation processes) have gained sufficient attention from drug developers owing to their ability to control the activity of genetically modified cell products in vivo while sparing host immune activity.
The Gene Switch Market - Distribution by Application Area (Management of Treatment Related Toxicity, Regulation of Gene Expression and Other Applications), Type of Target Therapy (CAR-T Cell Therapies, Gene Therapies and Other Therapies), Type of Payment Model Employed (Upfront Payments and Milestone Payments), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in the development of gene switch. The report answers many key questions related to this domain.
Gene switches are the sites on genes where regulatory molecules can bind to trigger the transcription and translational processes leading to the expression of that gene. Gene switching refers to reversible on / off switching of gene expression or switching of expression between two alleles of a gene. The expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. Certain regulatory proteins, or transcription factors, affect the transcription rate. Gene switches can be those regulatory proteins or specific DNA sequences that act to either switch on or off the expression of a gene.
Gene switches, also known as suicide switches / genetic switches / safety switches / molecular switches, are important components of genetic circuits that have wide applications in synthetic biology, gene therapy, and developmental biology. Gene switch platforms are widely employed for enhancing the safety of engineered T-cell therapies by incorporating reversible ON / OFF safety switches. Currently, several studies are underway to evaluate small molecule-based safety switches for various cell-based interventions. In addition, gene switches are used for controlling the expression of transgenes in various gene therapies without the requirement of additional protein components and to enhance the effector cell proliferation and lifespan extension of activated cell therapies leading to durable patient responses to therapeutics.
Presently, close to 50 industry and non-industry players are focused on the development / licensing of various types of gene switch platforms for an array of applications. The primary focus areas of these companies include management of treatment related toxicity, regulation of gene expression and other applications. The landscape features a mix of large, mid-sized and small companies. In addition, majority of the gene switch platforms are being used to mitigate the adverse events associated with CAR-T cell therapies.
Many stakeholders in this domain have been making consolidated efforts to forge alliances with other industry / non-industry players for gene switch research, licensing and co-development. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings in this domain. In this context, close to 150 articles focused on gene switch platforms have been published in high-impact journals, in the past five years. Furthermore, 350 patents related to gene switch platforms have been recently filed / granted, demonstrating the domain’s ongoing innovation.
The adoption of gene switch platforms to overcome the safety-related concerns associated with engineered cell therapies has increased in the recent past. The global gene switch market is anticipated to grow at an annualized growth rate (CAGR) of 14% during the period 2023-2035. It is worth highlighting that, in terms of target therapies, the gene switch market for CAR-T cell therapies is anticipated to grow at a relatively faster pace by 2035. Further, North America is anticipated to capture the major share of the gene switch market in 2035.
Examples of key players engaged in this domain (the complete list of players is available in the full report) include Autolus Therapeutics, aceRNA Technologies, Bellicum Pharmaceuticals, Kiromic Biopharma, Precigen, panCELLa and Sangamo Biosciences.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
| Report Attributes | Details | |
|
Forecast Period |
|
|
|
Type of Payment Model Employed |
|
|
|
Application Area |
|
|
|
Type of Target Therapy |
|
|
|
Key Geographical Regions |
|
|
|
Key Companies Profiled |
|
|
|
Customization Scope |
|
|
|
PowerPoint Presentation (Complimentary) |
|
|
|
Excel Data Packs |
|
|
The study presents detailed information on current market landscape and future opportunities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the gene switch market over the coming years. We have provided informed estimates on the likely evolution of the market for the period 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as application area (management of treatment related toxicity, regulation of gene expression and other applications), type of target therapy (CAR-T cell therapies, gene therapies and other therapies), type of payment model employed (upfront payments and milestone payments) and key geographical regions (North America, Europe, Asia-Pacific And Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Question 1: What are gene switches?
Answer: Gene switches are regulatory proteins or specific DNA sequences that act to either switch on or off the expression of a gene.
Question 2: What are the applications of gene switches?
Answer: The primary applications of gene switches include management of treatment related toxicity, regulation of gene expression and cell proliferation / persistence.
Question 3: What is the likely compound annual growth rate (CAGR) of the gene switch market?
Answer: The global gene switch market is expected to grow at a CAGR of 14%, during the period 2023-2035.
Question 4: Which region captures the largest share of the gene switch market?
Answer: Currently, North America captures the largest share of the global gene switch market. Further, Asia-Pacific is likely to grow at a considerable pace during the forecasted period.
Question 5: Which type of target therapy currently accounts for the largest share in the gene switch market?
Answer: The CAR-T cell therapies segment currently captures the largest share (60%) of the overall gene switch market. This trend is unlikely to change during the forecasted period.
Question 6: Which application area currently holds the largest share in the gene switch market?
Answer: Presently, the gene switches being used for the management of treatment related toxicity segment account for the largest share (56%) in the overall market.
Question 7: How many patents have been filed / granted related to gene switches in recent years?
Answer: More than 360 patents have been filed / granted for gene switches by various stakeholders, since 2017, indicating an increase in research, and subsequently, the expansion of intellectual capital in this domain.
Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Emergence of Gene Switch
3.2.1. Basic Components of Gene Switch
3.2.2. Mechanism of Action of Gene Switch
3.2.3. Type of Gene Regulation
3.3. Applications of Gene Switch
3.3.1. Endogenous Gene Regulation
3.3.2. Exogenous Gene Regulation
3.4. Challenges Associated with Gene Switch
3.5. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Gene Switch Platforms: Overall Market Landscape
4.2.1. Analysis by Type of Target Gene Switch
4.2.2. Analysis by Switch Activation
4.2.3. Analysis by Type of Activator / Repressor
4.2.4. Analysis by Application Area
4.2.5. Analysis by Type of Target Therapies
4.2.6. Analysis by Highest Phase of Development
4.2.7. Analysis by Target Therapeutic Area
4.3. Gene Switch Platform Developers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Organization
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis: Gene Switch Platforms
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. aceRNA Technologies
6.2.1. Company Overview
6.2.2. Gene Switch Platform Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Autolus Therapeutics
6.3.1. Company Overview
6.3.2. Gene Switch Platform Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Bellicum Pharmaceuticals
6.4.1. Company Overview
6.4.2. Gene Switch Platform Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Cellectis
6.5.1. Company Overview
6.5.2. Gene Switch Platform Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Kiromic BioPharma
6.6.1. Company Overview
6.6.2. Gene Switch Platform Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. panCELLa
6.7.1. Company Overview
6.7.2. Gene Switch Platform Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Precigen
6.8.1. Company Overview
6.8.2. Gene Switch Platform Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Sana Biotechnology
6.9.1. Company Overview
6.9.2. Gene Switch Platform Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sangamo Therapeutics
6.10.1. Company Overview
6.10.2. Gene Switch Platform Portfolio
6.10.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Gene Switch Platforms: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Application Area
7.3.4. Analysis by Year of Partnership and Application Area
7.3.5. Analysis by Type of Target Therapy
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Analysis by Geography
7.3.8.1 Intercontinental and Intracontinental Agreements
7.3.8.2 International and Local Agreements
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Gene Switch Platforms: Funding and Investments Analysis
8.3.1. Analysis of Instances by Year of Investment
8.3.2. Analysis of Amount Invested by Year of Investment
8.3.3. Analysis of Instances by Type of Funding
8.3.5. Analysis of Amount Invested by Type of Funding
8.3.6. Analysis of Instances by Type of Investor
8.3.7. Most Active Players: Analysis by Number of Instances
8.3.8. Most Active Players: Analysis by Amount Invested
8.3.9. Analysis of Amount Invested by Geography
8.3.9.1. Analysis by Region
8.3.9.2. Analysis by Country
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Gene Switch Platforms: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Article
9.3.3. Most Active Publishers: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Number of Publications
9.3.5. Analysis by Journal Impact Factor
9.3.6. Most Popular Journals: Analysis of Journal Impact Factor
9.3.7. Analysis by Key Focus Areas
9.3.8. Analysis by Affiliated Organization of Author
9.3.9. Most Popular Affiliation: Analysis by Number of Publications
9.3.10. Analysis by Geography
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Gene Switch Platforms: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. Gene Switch Platforms: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Gene Switch Platforms: Patent Valuation
10.6. Leading Patents: Analysis by Number of Citations
11. BUSINESS MODEL ANALYSIS
11.1. Chapter Overview
11.2. Gene Switch Platform Developers: Business Model Analysis
11.2.1. Analysis by Operational Model
11.2.2. Analysis by Service Centric Model
11.2.3. Analysis by Product Centric Model
11.3. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Gene Switch Platform Market, 2023-2035
12.3.1. Gene Switch Platform Market: Analysis by Application Area, 2023 and 2035
12.3.1.1. Gene Switch Market for Management of Treatment Related Toxicity, 2023-2035
12.3.1.2. Gene Switch Market for Regulation of Gene Expression, 2023-2035
12.3.1.3. Gene Switch Market for Other Applications, 2023-2035
12.3.2. Gene Switch Platform Market: Analysis by Type of Target Therapy, 2023 and 2035
12.3.2.1 Gene Switch Platform Market for CAR-T Cell Therapies, 2023-2035
12.3.2.2 Gene Switch Platform Market for Gene Therapies, 2023-2035
12.3.2.3 Gene Switch Platform Market for Other Therapies, 2023-2035
12.3.3. Gene Switch Platform Market: Analysis by Type of Payment Model Employed, 2023 and 2035
12.3.3.1. Gene Switch Platform Market for Upfront Payments, 2023-2035
12.3.3.2. Gene Switch Platform Market for Milestone Payments, 2023-2035
12.3.4. Gene Switch Platform Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Gene Switch Platform Market in North America, 2023-2035
12.3.4.2. Gene Switch Platform Market in Europe, 2023-2035
12.3.4.3. Gene Switch Platform Market in Asia Pacific, 2023-2035
12.3.4.4. Gene Switch Platform Market in Rest of the World, 2023-2035
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Business Model Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Gene Switch: Mechanism of Action
Figure 3.2 Gene Switch: Type of Gene Regulation
Figure 4.1 Gene Switch Platforms: Distribution by Type of Target Gene Switch
Figure 4.2 Gene Switch Platforms: Distribution by Switch Activation
Figure 4.3 Gene Switch Platforms: Distribution by Type of Activator / Repressor
Figure 4.4 Gene Switch Platforms: Distribution by Application Area
Figure 4.5 Gene Switch Platforms: Distribution by Type of Target Therapy
Figure 4.6 Gene Switch Platforms: Distribution by Highest Phase of Development
Figure 4.7 Gene Switch Platforms: Distribution by Target Therapeutic Area
Figure 4.8 Gene Switch Platform Developers: Distribution by Year of Establishment
Figure 4.9 Gene Switch Platform Developers: Distribution by Company Size
Figure 4.10 Gene Switch Platform Developer: Distribution by Type of Organization
Figure 4.11 Gene Switch Platform Developer: Distribution by Location of Headquarters (Region-wise)
Figure 4.12 Gene Switch Platform Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.13 Gene Switch Platform Developers: Distribution by Company Size and Location of Headquarters
Figure 5.1 Product Competitiveness Analysis: Dot-Plot Representation of Gene Switch Platforms
Figure 5.2 Product Competitiveness Analysis: Top Gene Switch Platforms
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Application Area
Figure 7.5 Partnerships and Collaborations: Distribution by Year of Partnership and Application Area
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Target Therapy
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.10 Partnerships and Collaborations: International and Local Agreements
Figure 8.1 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, 2019 – 2023
Figure 8.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, 2019 - 2023 (USD Million)
Figure 8.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 8.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 8.5 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Figure 8.6 Most Active Players: Distribution by Number of Instances
Figure 8.7 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 8.8 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Figure 8.9 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Figure 9.1 Publication Analysis: Distribution by Year of Publication
Figure 9.2 Publication Analysis: Distribution by Type of Article
Figure 9.3 Most Active Publishers: Distribution by Number of Publications
Figure 9.4 Most Popular Journals: Distribution by Number of Publications
Figure 9.5 Publications Analysis: Distribution by Journal Impact Factor
Figure 9.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 9.7 Publications Analysis: Distribution by Key Focus Areas
Figure 9.8 Publication Analysis: Distribution by Type of Affiliated Organization of Author
Figure 9.9 Most Popular Affiliation: Distribution by Number of Publications
Figure 9.10 Publication Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Figure 10.3 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre-2018-2022
Figure 10.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2017-2022
Figure 10.5 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 10.6 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 10.7 Patent Analysis: Distribution by CPC Symbols
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Individual Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Gene Switch: Patent Valuation
Figure 11.1 Gene Switch Platform Developers: Distribution by Operational Model
Figure 11.2 Gene Switch Platform Developers: Distribution by Company Size and Operational Model
Figure 11.3 Gene Switch Platform Developers: Distribution by Service Centric Model
Figure 11.4 Gene Switch Platform Developers: Distribution by Product Centric Model
Figure 12.1 Global Gene Switch Platform Market, 2023-2035 (USD Billion)
Figure 12.2 Gene Switch Platform Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Figure 12.3 Gene Switch Market for Management of Treatment Related Toxicity, 2023-2035 (USD Billion)
Figure 12.4 Gene Switch Market for Regulation of Gene Expression, 2023-2035 (USD Billion)
Figure 12.5 Gene Switch Market for Other Applications, 2023-2035 (USD Billion)
Figure 12.6 Gene Switch Platform Market: Distribution by Type of Target Therapy, 2023 and 2035 (USD Billion)
Figure 12.7 Gene Switch Platform Market for CAR-T Cell Therapies, 2023-2035 (USD Billion)
Figure 12.8 Gene Switch Platform Market for Gene Therapies, 2023-2035 (USD Billion)
Figure 12.9 Gene Switch Platform Market for Other Therapies, 2023-2035 (USD Billion)
Figure 12.10 Gene Switch Platform Market: Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Billion)
Figure 12.11 Gene Switch Platform Market for Upfront Payments, 2023-2035 (USD Billion)
Figure 12.12 Gene Switch Platform Market for Milestone Payments, 2023-2035 (USD Billion)
Figure 12.13 Gene Switch Platform Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Figure 12.14 Gene Switch Platform Market in North America, 2023-2035 (USD Billion)
Figure 12.15 Gene Switch Platform Market in Europe, 2023-2035 (USD Billion)
Figure 12.16 Gene Switch Platform Market in Asia Pacific, 2023-2035 (USD Billion)
Figure 12.17 Gene Switch Platform Market in Rest of the World, 2023-2035 (USD Billion)
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Product Competitiveness Analysis
Figure 13.3 Concluding Remarks: Partnerships and Collaborations
Figure 13.4 Concluding Remarks: Funding and Investments
Figure 13.5 Concluding Remarks: Patent Analysis
Figure 13.6 Concluding Remarks: Publication Analysis
Figure 13.7 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 4.1 Gene Switch Platforms: Information on Target Gene Switch, Activator / Repressor and Gene Switch Activation
Table 4.2 Gene Switch Platforms: Information on Application Area, Types of Target Therapies, Highest Phase of Development and Target Therapeutic Area
Table 4.3 List of Gene Switch Platform Developers
Table 6.1 Leading Gene Switch Developers
Table 6.2 aceRNA Technologies: Company Overview
Table 6.3 aceRNA Technologies: Gene Switch Platform Portfolio
Table 6.4 aceRNA Technologies: Recent Developments and Future Outlook
Table 6.5 Autolus Therapeutics: Company Overview
Table 6.6 Autolus Therapeutics: Gene Switch Platform Portfolio
Table 6.7 Autolus Therapeutics: Recent Developments and Future Outlook
Table 6.8 Bellicum Pharmaceuticals: Company Overview
Table 6.9 Bellicum Pharmaceuticals: Gene Switch Platform Portfolio
Table 6.10 Bellicum Pharmaceuticals: Recent Developments and Future Outlook
Table 6.11 Cellectis: Company Overview
Table 6.12 Cellectis: Gene Switch Platform Portfolio
Table 6.13 Cellectis: Recent Developments and Future Outlook
Table 6.14 Kiromic BioPharma: Company Overview
Table 6.15 Kiromic BioPharma: Gene Switch Platform Portfolio
Table 6.16 Kiromic BioPharma: Recent Developments and Future Outlook
Table 6.17 panCELLa: Company Overview
Table 6.18 panCELLa: Gene Switch Platform Portfolio
Table 6.19 panCELLa: Recent Developments and Future Outlook
Table 6.20 Precigen: Company Overview
Table 6.21 Precigen: Gene Switch Platform Portfolio
Table 6.22 Precigen: Recent Developments and Future Outlook
Table 6.23 Sana Biotechnology: Company Overview
Table 6.24 Sana Biotechnology: Gene Switch Platform Portfolio
Table 6.25 Sana Biotechnology: Recent Developments and Future Outlook
Table 6.26 Sangamo Therapeutics: Company Overview
Table 6.27 Sangamo Therapeutics: Gene Switch Platform Portfolio
Table 6.28 Sangamo Therapeutics: Recent Developments and Future Outlook
Table 7.1 Gene Switch Platforms: List of Partnerships and Collaborations, 2019-2023
Table 8.1 Gene Switch Platforms: List of Funding and Investments, 2019-2023
Table 8.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Patent Analysis: Distribution by CPC Symbols
Table 10.2 Patent Analysis: Top CPC Sections
Table 10.3 Patent Analysis: Top CPC Symbols
Table 10.4 Patent Analysis: Top CPC Codes
Table 10.5 Patent Analysis: Summary of Benchmarking Analysis
Table 10.6 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.7 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 10.8 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 12.1 Gene Switch Platforms: Average Upfront Payment and Average Milestone Payment, 2019-2023 (USD Million)
Table 14.1 Gene Switch Platforms: Distribution by Type of Target Gene Switch
Table 14.2 Gene Switch Platforms: Distribution by Switch Activation
Table 14.3 Gene Switch Platforms: Distribution by Type of Activator / Repressor
Table 14.4 Gene Switch Platforms: Distribution by Application Area
Table 14.5 Gene Switch Platforms: Distribution by Types of Target Therapies
Table 14.6 Gene Switch Platforms: Distribution by Highest Phase of Development
Table 14.7 Gene Switch Platforms: Distribution by Target Therapeutic Area
Table 14.8 Gene Switch Platform Developers: Distribution by Year of Establishment
Table 14.9 Gene Switch Platform Developers: Distribution by Company Size
Table 14.10 Gene Switch Platform Developer: Distribution by Type of Organization
Table 14.11 Gene Switch Platform Developer: Distribution by Location of Headquarters (Region-wise)
Table 14.12 Gene Switch Platform Developers: Distribution by Location of Headquarters (Country-wise)
Table 14.13 Gene Switch Platform Developers: Distribution by Company Size and Location of Headquarters
Table 14.14 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 14.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.16 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.17 Partnerships and Collaborations: Distribution by Application Area
Table 14.18 Partnerships and Collaborations: Distribution by Year of Partnership and Application Area
Table 14.19 Partnerships and Collaborations: Distribution by Type of Target Therapy
Table 14.20 Partnerships and Collaborations: Distribution by Type of Partner
Table 14.21 Most Active Players: Distribution by Number of Partnerships
Table 14.22 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.23 Partnerships and Collaborations: International and Local Agreements
Table 14.24 Funding and Investment Analysis: Cumulative Distribution of Number of Instances by Year, 2019 – 2023
Table 14.25 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, 2019 - 2023 (USD Million)
Table 14.26 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 14.27 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 14.28 Funding and Investment Analysis: Distribution of Instances by Type of Investor
Table 14.29 Most Active Players: Distribution by Number of Instances
Table 14.30 Most Active Players: Distribution by Amount Invested (USD Million)
Table 14.31 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
Table 14.32 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
Table 14.33 Publication Analysis: Distribution by Year of Publication
Table 14.34 Publication Analysis: Distribution by Type of Article
Table 14.35 Most Active Publishers: Distribution by Number of Publications
Table 14.36 Most Popular Journals: Distribution by Number of Publications
Table 14.37 Publications Analysis: Distribution by Journal Impact Factor
Table 14.38 Most Popular Journals: Distribution by Journal Impact Factor
Table 14.39 Publications Analysis: Distribution by Key Focus Areas
Table 14.40 Publication Analysis: Distribution by Type of Affiliated Organization
Table 14.41 Most Popular Affiliation: Distribution by Number of Publications
Table 14.42 Publication Analysis: Distribution by Geography
Table 14.43 Patent Analysis: Distribution by Type of Patent
Table 14.44 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Table 14.45 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre-2018-2022
Table 14.46 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2017-2022
Table 14.47 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 14.48 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 14.49 Patent Analysis: Distribution by CPC Symbols
Table 14.50 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.51 Leading Industry Players: Distribution by Number of Patents
Table 14.52 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.53 Leading Individual Assignees: Distribution by Number of Patents
Table 14.54 Patent Analysis: Distribution by Patent Age
Table 14.55 Gene Switch: Patent Valuation
Table 14.56 Gene Switch Platform Developers: Distribution by Operational Model
Table 14.57 Gene Switch Platform Developers: Distribution by Company Size and Operational Model
Table 14.58 Gene Switch Platform Developers: Distribution by Service Centric Model
Table 14.59 Gene Switch Platform Developers: Distribution by Product Centric Model
Table 14.60 Global Gene Switch Platform Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.61 Gene Switch Platform Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Table 14.62 Gene Switch Market for Management of Treatment Related Toxicity, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.63 Gene Switch Market for Regulation of Gene Expression, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.64 Gene Switch Market for Other Applications, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.65 Gene Switch Platform Market: Distribution by Type of Target Therapy, 2023 and 2035 (USD Billion)
Table 14.66 Gene Switch Platform Market for CAR-T Cell Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.67 Gene Switch Platform Market for Gene Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.68 Gene Switch Platform Market for Other Therapies, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.69 Gene Switch Platform Market: Distribution by Type of Payment Model Employed, 2023 and 2035 (USD Billion)
Table 14.70 Gene Switch Platform Market for Upfront Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.71 Gene Switch Platform Market for Milestone Payments, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.72 Gene Switch Platform Market: Distribution by Geography, 2023 and 2035 (USD Billion)
Table 14.73 Gene Switch Platform Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.74 Gene Switch Platform Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.75 Gene Switch Platform Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 14.76 Gene Switch Platform Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
Source 1: https://www.jci.org/articles/view/135754
Source 2: https://www.sciencedirect.com/science/article/pii/S0952791521000893
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES